| human | Q5 |
| P496 | ORCID iD | 0000-0001-5546-9680 |
| P1053 | ResearcherID | D-4393-2018 |
| P734 | family name | Kuypers | Q37463724 |
| Kuypers | Q37463724 | ||
| Kuypers | Q37463724 | ||
| P735 | given name | Dirk | Q1605531 |
| Dirk | Q1605531 | ||
| P106 | occupation | researcher | Q1650915 |
| Q77080891 | 'Full house' positive immunohistochemical membranoproliferative glomerulonephritis in a patient with portosystemic shunt |
| Q91664663 | A Peripheral Blood Gene Expression Signature to Diagnose Subclinical Acute Rejection |
| Q43631455 | A comparative prospective study on the use of low concentrate citrate lock versus heparin lock in permanent dialysis catheters. |
| Q33785079 | A highly sensitive liquid chromatography tandem mass spectrometry method for simultaneous quantification of midazolam, 1'-hydroxymidazolam and 4-hydroxymidazolam in human plasma. |
| Q40583419 | A new acute inflammatory syndrome related to the introduction of mycophenolate mofetil in patients with Wegener's granulomatosis |
| Q38838258 | A noninferiority trial comparing a heparin-grafted membrane plus citrate-containing dialysate versus regional citrate anticoagulation: results of the CiTED study. |
| Q44901262 | A prospective proof of concept study of the efficacy of tacrolimus ointment on uraemic pruritus (UP) in patients on chronic dialysis therapy |
| Q42789747 | A prospective, open-label, observational clinical cohort study of the association between delayed renal allograft function, tacrolimus exposure, and CYP3A5 genotype in adult recipients |
| Q43847327 | A prospective, randomized, double-blind crossover study on the use of 5% citrate lock versus 10% citrate lock in permanent hemodialysis catheters |
| Q45261113 | A simplified strategy for clinical management of late cytomegalovirus infection after oral ganciclovir prophylaxis in renal recipients |
| Q44598598 | A single-centre study of adjuvant cidofovir therapy for BK virus interstitial nephritis (BKVIN) in renal allograft recipients. |
| Q44441951 | A young patient with unexplained acute hepatorenal dysfunction |
| Q80291152 | Acute rejection in non-compliant renal allograft recipients: a distinct morphology |
| Q45247194 | Acute-onset, steroid-sensitive, encapsulating peritoneal sclerosis in a renal transplant recipient |
| Q46582078 | Adjuvant low-dose cidofovir therapy for BK polyomavirus interstitial nephritis in renal transplant recipients. |
| Q50218047 | Advancing Transplantation: New Questions, New Possibilities in Kidney and Liver Transplantation |
| Q90147342 | Age-related changes in DNA methylation affect renal histology and post-transplant fibrosis |
| Q78596121 | An uncommon tumor in a renal graft recipient: a diagnostic and therapeutic challenge |
| Q80174561 | An unusual cause of ureteral obstruction in a renal allograft |
| Q90515026 | Analyses of the short- and long-term graft survival after kidney transplantation in Europe between 1986 and 2015 |
| Q81452504 | Another devastating complication of the Schnitzler syndrome: AA amyloidosis |
| Q44866641 | Anti-CD20 monoclonal antibody (rituximab) treatment for hepatitis C-negative therapy-resistant essential mixed cryoglobulinemia with renal and cardiac failure |
| Q90940400 | Antibodies against ARHGDIB and ARHGDIB gene expression associate with kidney allograft outcome |
| Q96771813 | Antibody-mediated rejection with and without donor-specific anti-human leucocyte antigen antibodies: performance of the peripheral blood 8-gene expression assay |
| Q33406257 | Anticoagulation with fondaparinux for hemodiafiltration in patients with heparin-induced thrombocytopenia: dose-finding study and safety evaluation |
| Q39381264 | Aortic calcifications and arterial stiffness as predictors of cardiovascular events in incident renal transplant recipients |
| Q104556971 | Apixaban in patients on hemodialysis: a single dose pharmacokinetics study |
| Q84563404 | Apparent elevation of cyclosporine whole blood concentrations in a renal allograft recipient |
| Q81734497 | Artifactual hypocalcaemia after intravenous administration of gadodiamide (Omniscan) |
| Q89855734 | Assessing the Complex Causes of Kidney Allograft Loss |
| Q104479226 | Assessment of the Utility of Kidney Histology as a Basis for Discarding Organs in the United States: A Comparison of International Transplant Practices and Outcomes |
| Q36025615 | Associations of Soluble CD14 and Endotoxin with Mortality, Cardiovascular Disease, and Progression of Kidney Disease among Patients with CKD. |
| Q28253940 | Bartter's and Gitelman's syndromes: from gene to clinic |
| Q92683722 | Bone mineral density, bone turnover markers, and incident fractures in de novo kidney transplant recipients |
| Q73678539 | C3D deposition in peritubular capillaries indicates a variant of acute renal allograft rejection characterized by a worse clinical outcome |
| Q34945314 | Calcineurin inhibitor nephrotoxicity |
| Q37123164 | Calcium metabolism in the early posttransplantation period. |
| Q81897239 | Calcium requirements after parathyroidectomy in patients with refractory secondary hyperparathyroidism |
| Q33780255 | Cardiovascular disease relates to intestinal uptake of p-cresol in patients with chronic kidney disease |
| Q44583041 | Cessation of steroids in stable renal transplant patients: the Leuven experience |
| Q41702060 | Charcot neuroarthropathy after simultaneous pancreas-kidney transplantation: risk factors, prevalence, and outcome |
| Q44276263 | Chronic histological damage in early indication biopsies is an independent risk factor for late renal allograft failure. |
| Q91399903 | Clinical Inference of Serum and Bone Sclerostin Levels in Patients with End-Stage Kidney Disease |
| Q38748975 | Clinical determinants of calcineurin inhibitor disposition: a mechanistic review |
| Q43463833 | Clinical efficacy and toxicity profile of tacrolimus and mycophenolic acid in relation to combined long-term pharmacokinetics in de novo renal allograft recipients |
| Q44437966 | Clinical use of rapamycin in renal allograft recipients identifies its relevant toxicity profile and raises unsolved questions: a Single-Center experience |
| Q79775647 | Clinically relevant drug interaction between voriconazole and tacrolimus in a primary renal allograft recipient |
| Q45100343 | Combined 'en bloc' liver and pancreas transplantation in patients with liver disease and type 1 diabetes mellitus |
| Q85811327 | Combined effects of CYP3A5*1, POR*28, and CYP3A4*22 single nucleotide polymorphisms on early concentration-controlled tacrolimus exposure in de-novo renal recipients |
| Q44776130 | Combined kidney and intestinal transplantation in patients with enteric hyperoxaluria secondary to short bowel syndrome. |
| Q47400761 | Comparative performance of oral midazolam clearance and plasma 4β-hydroxycholesterol to explain interindividual variability in tacrolimus clearance. |
| Q46301570 | Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fixed-dose concentration-controlled trial |
| Q94673528 | Comparison of 2 Serum-Free Light-Chain Assays in CKD Patients |
| Q86221068 | Completeness and satisfaction with the education and information received by patients immediately after kidney transplant: a mixed-models study |
| Q50615779 | Criteria for HNF1B analysis in patients with congenital abnormalities of kidney and urinary tract. |
| Q46579648 | Current target ranges of mycophenolic acid exposure and drug-related adverse events: a 5-year, open-label, prospective, clinical follow-up study in renal allograft recipients. |
| Q37789484 | Cutaneous phaeohyphomycosis in renal allograft recipients: report of 2 cases and review of the literature |
| Q115016206 | Data-Driven Chronic Allograft Phenotypes: A Novel and Validated Complement for Histologic Assessment of Kidney Transplant Biopsies |
| Q39630789 | Decreased Circulating Sclerostin Levels in Renal Transplant Recipients With Persistent Hyperparathyroidism |
| Q92844878 | Delayed Bleeding of the Transplant Duodenum After Simultaneous Kidney-pancreas Transplantation: Case Series |
| Q46601873 | Detoxifying capacity and kinetics of prometheus--a new extracorporeal system for the treatment of liver failure |
| Q34202648 | Detoxifying capacity and kinetics of the molecular adsorbent recycling system. Contribution of the different inbuilt filters |
| Q92397058 | Development and validation of a peripheral blood mRNA assay for the assessment of antibody-mediated kidney allograft rejection: A multicentre, prospective study |
| Q34100487 | Dialysis techniques in the critically-ill patient |
| Q44250760 | Differential effect of diarrhea on FK506 versus cyclosporine A trough levels and resultant prevention of allograft rejection in renal transplant recipients. |
| Q101122203 | Discrepancies between bioimpedance spectroscopy devices in haemodialysis patients |
| Q33561691 | Donor age and renal P-glycoprotein expression associate with chronic histological damage in renal allografts |
| Q37149941 | Donor-specific antibodies require preactivated immune system to harm renal transplant. |
| Q46399178 | Drug interaction between itraconazole and sirolimus in a primary renal allograft recipient |
| Q46589242 | Drug interaction between mycophenolate mofetil and rifampin: possible induction of uridine diphosphate-glucuronosyltransferase |
| Q46824007 | Early clinical assessment of glucose metabolism in renal allograft recipients: diagnosis and prediction of post-transplant diabetes mellitus (PTDM). |
| Q51061124 | Effect of the Direct Oral Anticoagulants Rivaroxaban and Apixaban on the Disposition of Calcineurin Inhibitors in Transplant Recipients. |
| Q46428863 | Effects of CYP3A5 and MDR1 single nucleotide polymorphisms on drug interactions between tacrolimus and fluconazole in renal allograft recipients |
| Q36025085 | Effects of gastric emptying on oral mycophenolic acid pharmacokinetics in stable renal allograft recipients |
| Q46594092 | Efficacy and cardiovascular safety of daclizumab, mycophenolate mofetil, tacrolimus, and early steroid withdrawal in renal transplant recipients: a multicenter, prospective, pilot trial |
| Q98235850 | Eplet Mismatch Load and De Novo Occurrence of Donor-Specific Anti-HLA Antibodies, Rejection, and Graft Failure after Kidney Transplantation: An Observational Cohort Study |
| Q44364258 | Erosive enterocolitis in mycophenolate mofetil-treated renal-transplant recipients with persistent afebrile diarrhea |
| Q43472438 | Expression of CYP3A5 and P-glycoprotein in renal allografts with histological signs of calcineurin inhibitor nephrotoxicity |
| Q46577910 | Factors influencing technical success and outcome of percutaneous balloon angioplasty in de novo native hemodialysis arteriovenous fistulas |
| Q33944788 | Fibroblast growth factor-23 in early chronic kidney disease: additional support in favor of a phosphate-centric paradigm for the pathogenesis of secondary hyperparathyroidism |
| Q37560649 | Genome-Wide Association Study of Acute Renal Graft Rejection |
| Q80248561 | Heparin-coated polyacrylonitrile membrane versus regional citrate anticoagulation: a prospective randomized study of 2 anticoagulation strategies in patients at risk of bleeding |
| Q89058565 | High Intrapatient Variability of Tacrolimus Concentrations Predicts Accelerated Progression of Chronic Histologic Lesions in Renal Recipients |
| Q79693075 | High rate of Charcot foot attacks early after simultaneous pancreas-kidney transplantation |
| Q64091599 | Histological characteristics of Acute Tubular Injury during Delayed Graft Function predict renal function after renal transplantation |
| Q90941271 | Histological picture of antibody-mediated rejection without donor-specific anti-HLA antibodies: Clinical presentation and implications for outcome |
| Q92550169 | Hyperhomocysteinemia: a trigger for complement-mediated TMA? |
| Q43696325 | Hypotrichosis-lymphedema-telangiectasia-renal defect associated with a truncating mutation in the SOX18 gene |
| Q104611408 | Immunogenicity And Safety Of The Nine-Valent Human Papillomavirus Vaccine In Solid Organ Transplant Recipients And Hiv-Infected Adults |
| Q37400890 | Immunosuppression in pancreas transplantation: the Euro SPK trials and beyond |
| Q84143487 | Immunosuppression: does one regimen fit all? |
| Q46719586 | Immunosuppressive drugs after simultaneous pancreas-kidney transplantation. |
| Q45279289 | Impact of CYP3A5 genotype on tacrolimus versus midazolam clearance in renal transplant recipients: new insights in CYP3A5-mediated drug metabolism |
| Q46513111 | Impact of parathyroidectomy on renal graft function, blood pressure and serum lipids in kidney transplant recipients: a single centre study |
| Q82814338 | Impact of vascular calcification on corrected QT interval at the time of renal transplantation |
| Q61403449 | Improved Adherence to Tacrolimus Once-Daily Formulation in Renal Recipients |
| Q48080906 | In memoriam. Professor Dr Yves Vanrenterghem |
| Q44461502 | Influence of SDZ RAD vs. MMF on gastric emptying in renal transplant recipients |
| Q43895992 | Intracerebral haemorrhage caused by cefazoline-induced hypoprothrombinaemia in a renal transplant recipient |
| Q94470402 | Intrarenal arteriosclerosis and telomere attrition associate with dysregulation of the cholesterol pathway |
| Q86654191 | Intrarenal resistive index after renal transplantation |
| Q41483647 | Invasive aspergillosis after kidney transplant: case-control study. |
| Q58428552 | Ischemia-Induced DNA Hypermethylation during Kidney Transplant Predicts Chronic Allograft Injury |
| Q39035802 | Kidney Fibrosis: Origins and Interventions |
| Q44085395 | Kidney donation after circulatory death in a country with a high number of brain dead donors: 10-year experience in Belgium |
| Q44370012 | Kidney transplantation with rabbit antithymocyte globulin and sirolimus monotherapy |
| Q88464210 | Kuypers and Vanhove reply to 'Was 4β-hydroxycholesterol ever going to be a useful marker of CYP3A4 activity?' by Neuhoff and Tucker |
| Q44455054 | Living donor kidney transplantation: analysis of the first 40 cases performed in UZ Leuven. |
| Q44432001 | Localization, etiology and impact of calcium phosphate deposits in renal allografts. |
| Q44527309 | Long-term pharmacokinetic study of the novel combination of tacrolimus and sirolimus in de novo renal allograft recipients |
| Q90179308 | Long-term, prolonged-release tacrolimus-based immunosuppression in de novo kidney transplant recipients: 5-year prospective follow-up of the ADHERE study patients |
| Q43016480 | Maintenance immunosuppressive agents as risk factors for BK virus nephropathy: the need for true drug exposure measurements. |
| Q34405366 | Measuring total blood calcium displays a low sensitivity for the diagnosis of hypercalcemia in incident renal transplant recipients. |
| Q37069948 | Metabolism, Protein Binding, and Renal Clearance of Microbiota-Derived p-Cresol in Patients with CKD. |
| Q36031714 | Microbiota-Derived Phenylacetylglutamine Associates with Overall Mortality and Cardiovascular Disease in Patients with CKD. |
| Q41586193 | Microscopic nephrocalcinosis in chronic kidney disease patients. |
| Q82074811 | Mineral metabolism in renal transplant recipients discontinuing cinacalcet at the time of transplantation: a prospective observational study |
| Q79294815 | Multidrug resistance protein 2 genetic polymorphisms influence mycophenolic acid exposure in renal allograft recipients |
| Q44846330 | Mycophenolate mofetil in IgA nephropathy: results of a 3-year prospective placebo-controlled randomized study |
| Q45946479 | Mycophenolic acid exposure after administration of mycophenolate mofetil in the presence and absence of cyclosporin in renal transplant recipients. |
| Q58547302 | Natural history of mineral metabolism, bone turnover and bone mineral density in de novo renal transplant recipients treated with a steroid minimization immunosuppressive protocol |
| Q44782158 | Natural history of parathyroid function and calcium metabolism after kidney transplantation: a single-centre study |
| Q58617319 | Natural killer cell infiltration is discriminative for antibody-mediated rejection and predicts outcome after kidney transplantation |
| Q35635258 | Nephrogenic fibrosing dermopathy: a novel, disabling disorder in patients with renal failure |
| Q37523152 | New insights into the pharmacokinetics and pharmacodynamics of the calcineurin inhibitors and mycophenolic acid: possible consequences for therapeutic drug monitoring in solid organ transplantation |
| Q87042729 | Noncutaneous head and neck cancer in solid organ transplant patients: single center experience |
| Q91594231 | Occurrence of Diabetic Nephropathy After Renal Transplantation Despite Intensive Glycemic Control: An Observational Cohort Study |
| Q95433271 | Organ transplantation after cardiac death |
| Q36764338 | Parathyroidectomy after successful kidney transplantation: a single centre study |
| Q43665072 | Persistent hyperparathyroidism after kidney transplantation requiring parathyroidectomy. |
| Q92848526 | Persistent primary cytomegalovirus infection in a kidney transplant recipient: Multi-drug resistant and compartmentalized infection leading to graft loss |
| Q42954971 | Pharmacogenetic vs. Concentration-Controlled Optimization of Tacrolimus Dosing in Renal Allograft Recipients |
| Q39973995 | Phosphorus metabolism in peritoneal dialysis- and haemodialysis-treated patients. |
| Q81343755 | Polyomavirus interstitial nephritis and concurrent post-transplant lymphoma in a renal allograft: coincidence or more? |
| Q93069483 | Poor Vitamin K Status Is Associated With Low Bone Mineral Density and Increased Fracture Risk in End-Stage Renal Disease |
| Q54702468 | Post-streptococcal glomerulonephritis: not an extinct disease! |
| Q80216019 | Post-transplant lymphoma of the pancreatic allograft in a kidney-pancreas transplant recipient: a misleading presentation |
| Q53522735 | Postimplantation X-ray parameters predict functional catheter problems in peritoneal dialysis. |
| Q43811355 | Posttransplantation diabetes mellitus in FK-506-treated renal transplant recipients: analysis of incidence and risk factors |
| Q30235146 | Practical Recommendations for Long-term Management of Modifiable Risks in Kidney and Liver Transplant Recipients: A Guidance Report and Clinical Checklist by the Consensus on Managing Modifiable Risk in Transplantation (COMMIT) Group |
| Q90147875 | Prediction system for risk of allograft loss in patients receiving kidney transplants: international derivation and validation study |
| Q48295034 | Pretransplant 4β-hydroxycholesterol does not predict tacrolimus exposure or dose requirements during the first days after kidney transplantation. |
| Q84963162 | Prevalence and determinants of anemia in the immediate postkidney transplant period |
| Q36072508 | Progressive decline in tacrolimus clearance after renal transplantation is partially explained by decreasing CYP3A4 activity and increasing haematocrit |
| Q34518397 | Prometheus versus molecular adsorbents recirculating system: comparison of efficiency in two different liver detoxification devices |
| Q34483895 | Proteinuria as a Noninvasive Marker for Renal Allograft Histology and Failure: An Observational Cohort Study |
| Q33408239 | Reasons for dose reduction of mycophenolate mofetil during the first year after renal transplantation and its impact on graft outcome |
| Q36947345 | Recovery of hyperphosphatoninism and renal phosphorus wasting one year after successful renal transplantation |
| Q51764460 | Recurrence of light chain deposit disease after renal allograft transplantation: potential role of rituximab? |
| Q42997397 | Reduced C0 concentrations and increased dose requirements in renal allograft recipients converted to the novel once-daily tacrolimus formulation |
| Q43882854 | Regional citrate anticoagulation for hemodialysis using a conventional calcium-containing dialysate |
| Q91238791 | Relationship between In Vivo CYP3A4 Activity, CYP3A5 Genotype, and Systemic Tacrolimus Metabolite/Parent Drug Ratio in Renal Transplant Recipients and Healthy Volunteers |
| Q36350064 | Renal cell carcinoma in the allograft: what is the role of polyomavirus? |
| Q37246931 | Renal clearance and intestinal generation of p-cresyl sulfate and indoxyl sulfate in CKD. |
| Q77741159 | Renal transplantation for end-stage renal disease due to paroxysmal nocturnal haemoglobinuria |
| Q43654679 | Renal transplantation onto abnormal urinary tract: ileal conduit urinary diversion |
| Q100694648 | Replicative senescence and arteriosclerosis after kidney transplantation |
| Q42953764 | Response to 'Tacrolimus pharmacokinetics after kidney transplantation--Influence of changes in haematocrit and steroid dose'. |
| Q48268449 | Response to: 'Bodyweight-adjustments introduce significant correlations between CYP3A metrics and tacrolimus clearance'. |
| Q104682325 | Revisiting the changes in the Banff Classification for antibody-mediated rejection after kidney transplantation |
| Q54571062 | Rifampin induces alterations in mycophenolic acid glucuronidation and elimination: implications for drug exposure in renal allograft recipients. |
| Q44033366 | Role of immunosuppressive drugs in the development of tissue-invasive cytomegalovirus infection in renal transplant recipients. |
| Q46425733 | Secondary effects of immunosuppressive drugs after simultaneous pancreas-kidney transplantation |
| Q81410716 | Secondary renal amyloidosis due to long-standing tubulointerstitial nephritis in a patient with Sjögren syndrome |
| Q44891160 | Single-center analysis of biopsy-confirmed posttransplant lymphoproliferative disorder: incidence, clinicopathological characteristics and prognostic factors. |
| Q88015493 | Soluble urokinase receptor is a biomarker of cardiovascular disease in chronic kidney disease |
| Q91814128 | Specificity, strength, and evolution of pretransplant donor-specific HLA antibodies determine outcome after kidney transplantation |
| Q46834233 | Stability of mycophenolic acid and glucuronide metabolites in human plasma and the impact of deproteinization methodology. |
| Q39878612 | Stenosis detection in native hemodialysis fistulas with MDCT angiography |
| Q80470291 | Subclinical peritubular capillaritis at 3 months is associated with chronic rejection at 1 year |
| Q43043698 | Tacrolimus dose requirements and CYP3A5 genotype and the development of calcineurin inhibitor-associated nephrotoxicity in renal allograft recipients |
| Q36260230 | Telomere length, cardiovascular risk and arteriosclerosis in human kidneys: an observational cohort study |
| Q79947877 | Tertiary 'hyperphosphatoninism' accentuates hypophosphatemia and suppresses calcitriol levels in renal transplant recipients |
| Q98302423 | The Histological Picture of Indication Biopsies in the First 2 Weeks after Kidney Transplantation |
| Q35786047 | The Influence of CKD on Colonic Microbial Metabolism |
| Q34498094 | The Influence of Dietary Protein Intake on Mammalian Tryptophan and Phenolic Metabolites. |
| Q35995858 | The Influence of Prebiotic Arabinoxylan Oligosaccharides on Microbiota Derived Uremic Retention Solutes in Patients with Chronic Kidney Disease: A Randomized Controlled Trial |
| Q61718362 | The Once-Daily Formulation of Tacrolimus |
| Q84575138 | The P450 oxidoreductase *28 SNP is associated with low initial tacrolimus exposure and increased dose requirements in CYP3A5-expressing renal recipients |
| Q36805870 | The accuracy of positron emission tomography in the detection of posttransplant lymphoproliferative disorder |
| Q96432047 | The association between use of proton-pump inhibitors and excess mortality after kidney transplantation: A cohort study |
| Q83429549 | The bumpy road of genomic medicine in transplantation: lessons from studies on calcineurin inhibitor nephrotoxicity |
| Q93244758 | The clinical importance of extended 2nd field high-resolution HLA genotyping for kidney transplantation |
| Q89123249 | The clinical significance of epitope mismatch load in kidney transplantation: A multicentre study |
| Q98952786 | The effect of IGL-1 preservation solution on outcome after kidney transplantation: A retrospective single-center analysis |
| Q40410816 | The effect of anastomosis time on outcome in recipients of kidneys donated after brain death: a cohort study |
| Q43752519 | The effect of mycophenolate mofetil on hepatitis B viral load in stable renal transplant recipients with chronic hepatitis B. |
| Q100318218 | The effect of universal infant vaccination on the prevalence of hepatitis B immunity in adult solid organ transplant candidates |
| Q38919797 | The functional implications of common genetic variation in CYP3A5 and ABCB1 in human proximal tubule cells. |
| Q34439824 | The histology of kidney transplant failure: a long-term follow-up study. |
| Q80798786 | The impact of renal allograft function on exposure and elimination of mycophenolic acid (MPA) and its metabolite MPA 7-O-glucuronide |
| Q46731220 | The impact of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients |
| Q46582267 | The influence of renal transplantation on retained microbial-human co-metabolites |
| Q41828910 | The predictive value of kidney allograft baseline biopsies for long-term graft survival |
| Q45071155 | The rate of gastric emptying determines the timing but not the extent of oral tacrolimus absorption: simultaneous measurement of drug exposure and gastric emptying by carbon-14-octanoic acid breath test in stable renal allograft recipients |
| Q87055318 | The soluble urokinase receptor is not a clinical marker for focal segmental glomerulosclerosis |
| Q44461526 | The use of an anti-CD25 monoclonal antibody and mycophenolate mofetil enables the use of a low-dose tacrolimus and early withdrawal of steroids in renal transplant recipients. |
| Q43801418 | The value of tuberculin skin testing in haemodialysis patients. |
| Q36455259 | Therapeutic drug monitoring of mycophenolate mofetil in transplantation |
| Q88139167 | Time course of asymmetric dimethylarginine and symmetric dimethylarginine levels after successful renal transplantation |
| Q45011560 | Time-related clinical determinants of long-term tacrolimus pharmacokinetics in combination therapy with mycophenolic acid and corticosteroids: a prospective study in one hundred de novo renal transplant recipients |
| Q97530146 | Transcriptional Changes in Kidney Allografts with Histology of Antibody-Mediated Rejection without Anti-HLA Donor-Specific Antibodies |
| Q82848881 | Troponin I is a predictor of acute cardiac events in the immediate postoperative renal transplant period |
| Q47799865 | Tubulointerstitial expression and urinary excretion of connective tissue growth factor 3 months after renal transplantation predict interstitial fibrosis and tubular atrophy at 5 years in a retrospective cohort analysis. |
| Q49129696 | Two-tier approach for the detection of alpha-galactosidase A deficiency in kidney transplant recipients |
| Q34984788 | UGT1A9 -275T>A/-2152C>T polymorphisms correlate with low MPA exposure and acute rejection in MMF/tacrolimus-treated kidney transplant patients |
| Q88021982 | Updated Manufacturer and European Medicines Agency Recommendations on the Use of Mycophenolate Acid: Balancing the Risks for Male Allograft Recipients |
| Q50876181 | Urinary connective tissue growth factor is associated with human renal allograft fibrogenesis. |
| Q33944858 | p-Cresol and cardiovascular risk in mild-to-moderate kidney disease |
Search more.